Dociparstat sodium API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Dociparstat sodium API 177021-00-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Dociparstat sodium. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Dociparstat sodium
- Synonyms:
- 2,3-o-Desulfated heparin (12000 da) , Dociparstat sodium
- Cas Number:
- 177021-00-0
- DrugBank number:
- DB16481
- Unique Ingredient Identifier:
- 4O75889WF4
General Description:
Dociparstat sodium is a chemical compound identified by the CAS number 177021-00-0.
Mechanism of Action:
Dociparstat sodium functions by: Dociparstat sodium is derived from heparin which, like heparin, alters the activities of the CXCL12/CXCR4 axis and inhibits the interactions of proteins including P-selectin, high mobility group box 1, Platelet Factor 4, and human leukocyte elastase. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Dociparstat sodium is categorized under the following therapeutic classes: Anticoagulants, Carbohydrates, Experimental Unapproved Treatments for COVID-19, Glycosaminoglycans, Heparin and similars, Polysaccharides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Dociparstat sodium is a type of Anticoagulants
Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.
There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.
Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.
While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.
In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.
